“Effective, low-cost diagnostics and screening tests in cancer are especially important in regions in which wide access to advanced, expensive diagnostics tools and procedures is not readily available or accessible” said Arnon Chait, Ph.D., President of AnalizaDx, “Our technology platform provides lab-based solutions that could bring definitive answers to millions using blood-based analysis of protein biomarker structure.”
Under the terms of the license agreement, GHMI will enter markets in Africa, beginning with Nigeria and South Africa. Through its network of collaborations with leading hospitals and clinical laboratories, GHMI will begin offering AnalizaDx’s PSA/SIA, a next generation prostate cancer test that has demonstrated superior performance in differentiating between prostate cancer and other benign conditions using blood sample. Follow-on tests will target breast, colon, ovarian, and other cancers.
“We are pleased to enter into this ground-breaking agreement to allow us to offer a series of advanced low-cost cancer tests throughout the African continent. We believe this partnership will result in many saved lives, while making good use of precious healthcare resources in both developed and emerging markets in Africa” said Debo Awosika-Olumo, MD, President and CEO of GHMI. “With operations in the U.S. and Africa, we plan to enable smooth transfer of technology and diagnostics products in the near future.”
GHMI headquartered in Houston, TX, is a diversified company focusing on bringing advanced healthcare solutions to emerging markets. GHMI specializes in providing expert global health business solutions for global challenges such as health, research and evaluation, and health information technology. GHMI core areas are strategic developments;
For more information regarding GHMI please visit globalhealthmanagementinformatics.com.
AnalizaDx is a cancer diagnostics company headquartered in Cleveland, OH. The company advances unique diagnostics products in cancer centered on rapid evaluation of changes to the structure of protein biomarkers in biological fluids, in contrast with the current diagnostics modalities centered on measuring changes to their amount. Changes to protein structure are inherently connected to cancer, a disease characterized by underlying genetic mutations that result in changes in the corresponding proteins. AnalizaDx core technology, Solvent Interaction Analysis, represents a simple addition to current clinical immunoassays and is conducted using conventional automated laboratory instruments.
For more information regarding AnalizaDx please visit http://www.analizadx.com.
Debo Awosika-Olumo, MD